



TEOSYAL PURESENSE

# Redensity [II] Eyes


A different gel designed  
for **Eye Circles**

LABORATORIES  
**TEOXANE**  
GENEVA


[www.teoxane.com](http://www.teoxane.com)

# EYES CIRCLES, A DELICATE AREA

## ➔ ANATOMICAL AND HISTOLOGICAL LANDMARKS




- ① Fine skin, low level of hyaluronidase
- ② Supraorbicular fat
- ③ Orbicular muscle
- ④ Suborbital fat (SOOF)
- ⑤ Periosteum




- ① Palpebral line
- ① Tear trough
- ② Palpebromalar groove
- ③ Mediojugal fold
- ④ Nasolabial fold

## ➔ ANATOMICAL SPECIFICITIES OF THE SUBORBITAL AREA



A complex lymphatic system



High risk areas : ① Angular artery  
② Emergence of the infraorbital nerve V2



# Redensity [II] Eyes



## A DIFFERENT GEL DESIGNED TO TREAT EYE CIRCLES FOR A NATURAL AND LONG LASTING CORRECTION

### ➔ A SOPHISTICATED AND SYNERGISTIC 3-IN-1 FORMULA, COMBINING NATURAL INGREDIENTS


<b>SEMI-CROSSLINKED HYALURONIC ACID (HA)</b> <b>15 mg/g</b> Mix of cross-linked <sup>(1)</sup> HA (BDDE) and non cross-linked HA	+	<b>DERMO-RESTRUCTURING COMPLEX <sup>(2)</sup></b> <b>8 amino acids:</b> Glycine, Lysine, Threonine, Proline, Isoleucine, Leucine, Valine, Arginine <b>3 antioxydants:</b> Glutathion, N-Acetyl-L-cysteine, Alphalipoic acid <b>2 minerals:</b> Zinc and Copper <b>1 vitamin:</b> B6	+	<b>LIDOCAINE</b>
---	---	---	---	------------------

### ➔ A SUBTLE BALANCE BETWEEN A LOW LEVEL OF HA AND A SEMI-CROSSLINKED HA: A LOW HYGROSCOPIC ACTIVITY

- To **reduce the risk of oedema and swelling** with a quantity < 0.5ml by eye circle.<sup>(3)</sup>

### ➔ AN IDEAL VISCOELASTICITY: HIGH SPREADING CAPABILITY

- To **maximise the ease of injection** (81%\*) and **positioning** (100%\*).\*<sup>(3)</sup>



Photos: Teoxane data source

### ➔ A LIGHT GEL WHICH EXERTS LOW PRESSURE ON THE TISSUES

- To **reduce risk of oedema**.<sup>(3)</sup>

(1) From the patented technology RHA: Resilient Hyaluronic Acid™

(2) Patent pending technology

(3) Phase III multicentric clinical study of 67 patients followed during 1 year (2010)

\* Practitioners evaluation

# Redensity [II] Eyes



## SAFETY AND EFFICACY RESULTS – PHASE III STUDY <sup>(1)</sup>

### ➔ CLINICAL PROTOCOL

- Multicentric clinical trial held by 6 practitioners with 67 patients
- Follow-up: 1 year
- 5 visits: injection on day 1, check-up at 15 days, 1 month, 3 months, 6 months and 12 months
- GAIS\* cross-evaluation
- No touch-up in 72% of cases. Touch-up only for patients injected with 0.2 ml at first

### ➔ EFFICIENCY RESULTS

- **PATIENT N° 1**
  - Indications: tear trough deformity
  - Injected volume: 0.15 ml on right side and 0.20 ml on left side
  - Slow injection

BEFORE




AFTER  
Immediate result after injection




- **PATIENT N° 2**
  - Indications: tear trough deformity and Palpebromalar groove
  - Injected volume: 0.20 ml per side
  - Slow injection

BEFORE



AFTER  
Immediate result after injection



(1) Phase III multicentric clinical study of 67 patients followed during 1 year (2010)


\* GAIS : Global Aesthetic Improvement Scale

# Redensity [II] Eyes



## SAFETY AND EFFICACY RESULTS – PHASE III STUDY <sup>(1)</sup>

### ➔ HIGH DEGREE OF SATISFACTION : PATIENTS AND PRACTITIONERS EVALUATION



The majority of patients were satisfied with the results immediately after injection, at month-6 and month-12 and would recommend it to their relatives. <sup>(1)</sup>

### ➔ RECOGNIZED TOLERANCE OVER 1 YEAR

- The safety of Teosyal® PureSense Redensity [II] was demonstrated with an average injected volume of 0.37 ml per eye circle
- Out of 67 patients:
  - 4 cases of transitional side effects were noted. Redness and post-injection bruising disappeared within 72h after injection
  - 1 single case of oedema was observed. The oedema resorbed spontaneously in less than 1 month (0.6ml injected)
  - No tyndall effect was observed

<sup>(1)</sup> Phase III multicentric clinical study of 67 patients followed during 1 year (2010)

\* GAIS : Global Aesthetic Improvement Scale



# Redensity [II] Eyes



## DIAGNOSIS: AN ESSENTIAL STEP

### ➞ APPROPRIATE DIAGNOSIS OF EYE CIRCLES FOR OPTIMAL EFFICACY AND TOLERABILITY

- Sit the patient for diagnosis and evaluation in a semi-reclined position
- Exert a slight pressure on the eye before the injection to help:
  - Determine the orbital margin
  - Detect any lymphatic insufficiency
- Perform a snap test to ensure there is no excessive palpebral looseness


### ➞ TEOSYAL® PURESENSE REDENSITY [II] INDICATIONS

- Eye Circles
- Tear trough
- Palpebromalar groove
- Minimal palpebral or malar bags

*For malar and jugal area, use more volumising fillers*




Teoxane data source



Teoxane data source


### ➞ WRONG INDICATIONS

- Exclusively pigmentary dark circles
- Large palpebral or malar bags



Photos: S. Poignonec (France)

Pigmentary dark circles



Photos: S. Poignonec (France)

Large palpebral bags


TEOSYAL PURESENSE

# Redensity [II] Eyes


## A PRECISE INJECTION TECHNIQUE

### ➔ INJECTION TECHNIQUES

- Slow injection
- Deep supra-periosteal
- Sub-orbicular



Microbolus technique  
with needle



Retrograde technique  
with cannula

### ➔ RECOMMENDED DOSE

- **Quantity for each eye circle < 0.5ml:**

To obtain maximum safety and good long-term results, it is strongly recommended not to inject more than 0.5 ml of Teosyal® PureSense Redensity [II] in each eye circle

### ➔ PROTOCOL

- **First session:** under correction is recommended
- **Touch-up session:** 1 month later, only if necessary

### ➔ TEOSYAL® PURESENSE REDENSITY [II]

- **Package:** 2 x 1 ml
- **CE marking:** class III





SWISS INNOVATION APPLIED TO BEAUTY



Les Charmilles - Rue de Lyon, 105 - CH 1203 Genève  
Tél. : +41 (0) 22 344 96 36 - Fax : +41 (0) 22 340 29 33

General information: [info@teoxane.com](mailto:info@teoxane.com)

Medical information department: [medical@teoxane.com](mailto:medical@teoxane.com)

[www.teoxane.com](http://www.teoxane.com)